vs
Loar Holdings Inc.（LOAR）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Loar Holdings Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.9倍（$131.8M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 9.5%，领先374.5%），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 19.3%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 19.8%）
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
LOAR vs RIGL — 直观对比
营收规模更大
LOAR
是对方的1.9倍
$69.8M
营收增速更快
RIGL
高出1.9%
19.3%
净利率更高
RIGL
高出374.5%
9.5%
两年增速更快
RIGL
近两年复合增速
19.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $131.8M | $69.8M |
| 净利润 | $12.5M | $268.1M |
| 毛利率 | 52.1% | 91.5% |
| 营业利润率 | 18.0% | 33.2% |
| 净利率 | 9.5% | 384.0% |
| 营收同比 | 19.3% | 21.2% |
| 净利润同比 | 239.5% | 1769.2% |
| 每股收益（稀释后） | $0.13 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LOARRIGL
| Q4 25 | $131.8M | $69.8M | ||
| Q3 25 | $126.8M | $69.5M | ||
| Q2 25 | $123.1M | $101.7M | ||
| Q1 25 | $114.7M | $53.3M | ||
| Q4 24 | $110.4M | $57.6M | ||
| Q3 24 | $103.5M | $55.3M | ||
| Q2 24 | $97.0M | $36.8M | ||
| Q1 24 | $91.8M | $29.5M |
净利润LOARRIGL
| Q4 25 | $12.5M | $268.1M | ||
| Q3 25 | $27.6M | $27.9M | ||
| Q2 25 | $16.7M | $59.6M | ||
| Q1 25 | $15.3M | $11.4M | ||
| Q4 24 | $3.7M | $14.3M | ||
| Q3 24 | $8.7M | $12.4M | ||
| Q2 24 | $7.6M | $-1.0M | ||
| Q1 24 | $2.2M | $-8.2M |
毛利率LOARRIGL
| Q4 25 | 52.1% | 91.5% | ||
| Q3 25 | 52.7% | 93.2% | ||
| Q2 25 | 53.8% | 95.6% | ||
| Q1 25 | 52.1% | 91.7% | ||
| Q4 24 | 48.9% | 89.9% | ||
| Q3 24 | 51.1% | 85.5% | ||
| Q2 24 | 49.0% | 92.4% | ||
| Q1 24 | 48.4% | 93.1% |
营业利润率LOARRIGL
| Q4 25 | 18.0% | 33.2% | ||
| Q3 25 | 22.9% | 40.9% | ||
| Q2 25 | 22.2% | 60.1% | ||
| Q1 25 | 22.8% | 23.9% | ||
| Q4 24 | 19.2% | 28.9% | ||
| Q3 24 | 22.1% | 25.4% | ||
| Q2 24 | 22.9% | 1.2% | ||
| Q1 24 | 23.3% | -23.6% |
净利率LOARRIGL
| Q4 25 | 9.5% | 384.0% | ||
| Q3 25 | 21.8% | 40.2% | ||
| Q2 25 | 13.6% | 58.6% | ||
| Q1 25 | 13.4% | 21.5% | ||
| Q4 24 | 3.3% | 24.9% | ||
| Q3 24 | 8.4% | 22.5% | ||
| Q2 24 | 7.9% | -2.8% | ||
| Q1 24 | 2.4% | -27.9% |
每股收益（稀释后）LOARRIGL
| Q4 25 | $0.13 | $14.11 | ||
| Q3 25 | $0.29 | $1.46 | ||
| Q2 25 | $0.17 | $3.28 | ||
| Q1 25 | $0.16 | $0.63 | ||
| Q4 24 | $-11023.48 | $0.82 | ||
| Q3 24 | $0.09 | $0.70 | ||
| Q2 24 | $0.09 | $-0.06 | ||
| Q1 24 | $11023.54 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $84.8M | $155.0M |
| 总债务越低越好 | $715.7M | $52.5M |
| 股东权益账面价值 | $1.2B | $391.5M |
| 总资产 | $2.0B | $513.6M |
| 负债/权益比越低杠杆越低 | 0.61× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资LOARRIGL
| Q4 25 | $84.8M | $155.0M | ||
| Q3 25 | $99.0M | $137.1M | ||
| Q2 25 | $103.3M | $108.4M | ||
| Q1 25 | $80.5M | $77.1M | ||
| Q4 24 | $54.1M | $77.3M | ||
| Q3 24 | $55.2M | $61.1M | ||
| Q2 24 | $73.2M | $49.1M | ||
| Q1 24 | $28.2M | $49.5M |
总债务LOARRIGL
| Q4 25 | $715.7M | $52.5M | ||
| Q3 25 | $279.4M | $60.0M | ||
| Q2 25 | $277.7M | $60.0M | ||
| Q1 25 | $277.5M | $60.0M | ||
| Q4 24 | $277.3M | $60.0M | ||
| Q3 24 | $602.1M | $60.0M | ||
| Q2 24 | $250.7M | $60.0M | ||
| Q1 24 | $534.2M | $60.0M |
股东权益LOARRIGL
| Q4 25 | $1.2B | $391.5M | ||
| Q3 25 | $1.2B | $117.6M | ||
| Q2 25 | $1.1B | $81.9M | ||
| Q1 25 | $1.1B | $18.6M | ||
| Q4 24 | $1.1B | $3.3M | ||
| Q3 24 | $769.8M | $-14.6M | ||
| Q2 24 | $758.4M | $-29.9M | ||
| Q1 24 | $420.6M | $-31.7M |
总资产LOARRIGL
| Q4 25 | $2.0B | $513.6M | ||
| Q3 25 | $1.5B | $242.5M | ||
| Q2 25 | $1.5B | $206.7M | ||
| Q1 25 | $1.5B | $176.0M | ||
| Q4 24 | $1.5B | $164.0M | ||
| Q3 24 | $1.5B | $139.4M | ||
| Q2 24 | $1.1B | $128.4M | ||
| Q1 24 | $1.1B | $126.5M |
负债/权益比LOARRIGL
| Q4 25 | 0.61× | 0.13× | ||
| Q3 25 | 0.24× | 0.51× | ||
| Q2 25 | 0.25× | 0.73× | ||
| Q1 25 | 0.25× | 3.23× | ||
| Q4 24 | 0.25× | 18.25× | ||
| Q3 24 | 0.78× | — | ||
| Q2 24 | 0.33× | — | ||
| Q1 24 | 1.27× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 2.43× | 0.08× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LOARRIGL
| Q4 25 | $30.4M | $22.0M | ||
| Q3 25 | $29.7M | $24.0M | ||
| Q2 25 | $23.8M | $30.5M | ||
| Q1 25 | $28.4M | $-893.0K | ||
| Q4 24 | $20.7M | $14.5M | ||
| Q3 24 | $16.3M | $21.7M | ||
| Q2 24 | $7.1M | $302.0K | ||
| Q1 24 | $10.8M | $-5.0M |
现金转化率LOARRIGL
| Q4 25 | 2.43× | 0.08× | ||
| Q3 25 | 1.08× | 0.86× | ||
| Q2 25 | 1.42× | 0.51× | ||
| Q1 25 | 1.85× | -0.08× | ||
| Q4 24 | 5.62× | 1.01× | ||
| Q3 24 | 1.89× | 1.75× | ||
| Q2 24 | 0.93× | — | ||
| Q1 24 | 4.81× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LOAR
| Other | $76.8M | 58% |
| Commercial Aerospace | $21.2M | 16% |
| Business Jet And General Aviation | $17.6M | 13% |
| Defense | $16.2M | 12% |
RIGL
暂无分部数据
